MCID: NPH018
MIFTS: 43

Nephrogenic Systemic Fibrosis malady

Rare diseases, Skin diseases, Nephrological diseases categories

Aliases & Classifications for Nephrogenic Systemic Fibrosis

About this section
Sources:
45NIH Rare Diseases, 51Orphanet, 65UMLS, 66UMLS via Orphanet
See all sources

Aliases & Descriptions for Nephrogenic Systemic Fibrosis:

Name: Nephrogenic Systemic Fibrosis 45 51
Nephrogenic Fibrosing Dermopathy 45 51 65
 
Nfd 45
Nsf 45


Classifications:

Orphanet: 51 
Rare skin diseases


External Ids:

Orphanet51 137617
UMLS via Orphanet66 C1619692

Summaries for Nephrogenic Systemic Fibrosis

About this section
NIH Rare Diseases:45 Nephrogenic systemic fibrosis is a condition that affects different parts of the body, particularly the skin. symptoms of the condition may include progressive swelling and tightening of the skin, sometimes resulting in contractures, and pruritis (itching).  the skin findings are similar to those seen in patients with scleroderma.  nephrogenic systemic fibrosis was first described in 1997. being exposed to gadolinium-containing contrast agents during mri testing has been identified as a significant risk factor for development of this disease. last updated: 4/24/2013

MalaCards based summary: Nephrogenic Systemic Fibrosis, also known as nephrogenic fibrosing dermopathy, is related to kidney disease and skin conditions. An important gene associated with Nephrogenic Systemic Fibrosis is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase, Catalytic Subunit Alpha), and among its related pathways are Paxillin-dependent events mediated by a4b1 and G-protein signaling_K-RAS regulation pathway. Affiliated tissues include skin, kidney and testes, and related mouse phenotypes are liver/biliary system and renal/urinary system.

Wikipedia:68 Nephrogenic systemic fibrosis (NSF) or nephrogenic fibrosing dermopathy is a rare and serious syndrome... more...

Related Diseases for Nephrogenic Systemic Fibrosis

About this section

Graphical network of the top 20 diseases related to Nephrogenic Systemic Fibrosis:



Diseases related to nephrogenic systemic fibrosis

Symptoms for Nephrogenic Systemic Fibrosis

About this section

Drugs & Therapeutics for Nephrogenic Systemic Fibrosis

About this section

Drugs for Nephrogenic Systemic Fibrosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 13)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
GadodiamideapprovedPhase 47122795-43-160754
Synonyms:
Gadodiamida
Gadodiamide
Gadodiamide hydrate
 
Gadodiamidum
Gadolinium 5,8-bis(carboxylatomethyl)-11-[2-(methylamino)-2-oxoethyl]-3-oxo-2,5,8,11-tetraazatridecan-13-oate hydrate
Gadolinium [bis(2-{(carboxylatomethyl)[2-(methylamino)-2-oxoethyl]amino}ethyl)amino]acetate--water (1/1)
Omniscan
2
GadobutrolapprovedPhase 447138071-82-615814656
Synonyms:
 
Gadavist
gadolinium(III) 2,2',2''-(10-((2R,3S )-1,3,4-trihydroxybutan-2-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetate
3Gadolinium DTPAPhase 482
4Gadolinium ethoxybenzyl DTPAPhase 4, Phase 329
5Gadobenic acidPhase 482
6
imatinibapprovedPhase 3, Phase 2567152459-95-5644241, 5291
Synonyms:
112GI019
152459-95-5
1iep
1xbb
4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE
4-(4-METHYL-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide
4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide
4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-benzamide methanesulfonate
4-[(4-methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)pyrimidin-2-yl]amino}phenyl)benzamide
4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
4-[(4-methylpiperazin-1-yl)methyl]-N-{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl}benzamide
AC-524
AC1L1K0Z
AKOS000280662
BIDD:GT0047
BRD-K92723993-066-02-9
Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]- (9CI)
CCRIS 9076
CGP 57148B
CGP57148
CGP57148B
CHEBI:45783
CHEMBL941
CID5291
Cgp 57148
D08066
DB00619
DB03261
EN002706
FT-0083542
Glamox
Glamox (TN)
 
Gleevec
Glivec
HMS2089D03
I01-1232
Imatinib
Imatinib (INN)
Imatinib Mesylate
Imatinib Methansulfonate
Imatinib [INN:BAN]
Imatinib free base
Imatinibum
Kinome_3724
LS-182208
LS-187106
MolPort-000-883-342
N-(3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)-4-methylphenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide
NCGC00159456-02
NCGC00159456-03
NCGC00159456-04
NSC743414
STI
STI 571
STI-571
STI571
STK617705
UNII-BKJ8M8G5HI
alpha-(4-Methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-P-toluidide
alpha-(4-Methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-tolu-p-toluidide
imatinib
nchembio.117-comp23
nchembio.162-comp5
nchembio.282-comp6
nchembio.83-comp14
sti-571
7Plasma-lyte 148Phase 1, Phase 244
8
Gadofosveset trisodiumapproved20193901-90-523724913
Synonyms:
Ablavar
 
Gadofosveset
MS-325
Vasovist
9
Gadoteridolapproved7120066-54-860714
Synonyms:
GD-HP-do 3a
Gadolinium 2,2',2''-[10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetate
Gadolinium-HP-do3a
 
Gadoteridol
Gadoteridolum
Gd-hpdo3a
Prohance
10
Gadoversetamideapproved, investigational7131069-91-5444013
Synonyms:
Gadoversetamid
Gadoversetamida
Gadoversetamide
 
Gadoversetamide [USAN:INN:BAN]
Gadoversetamidum
OptiMARK
Optimark
11
Iodine4597553-56-2807
Synonyms:
I2
Iode
Iodine-molecule
 
Iodio
Iodum
Jod
Jood
Tincture iodine
12Gadoterate meglumine26
13cadexomer iodine425

Interventional clinical trials:

(show all 22)
idNameStatusNCT IDPhase
1Primovist / Eovist in Renally Impaired PatientsCompletedNCT00908596Phase 4
2Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of MagnevistCompletedNCT00744939Phase 4
3Safety of Gadovist in Renally Impaired PatientsCompletedNCT00828737Phase 4
4Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)CompletedNCT00908310Phase 4
5Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF)TerminatedNCT01078987Phase 4
6Treatment of Patients With Nephrogenic Systemic Fibrosis With GlivecCompletedNCT00981942Phase 3
7Efficacy and Safety of Primovist in Chinese PatientsCompletedNCT00526188Phase 3
8Nephrogenic Systemic Fibrosis With GadollinumEnrolling by invitationNCT01359345Phase 2, Phase 3
9The Effect of Crystalloids and Colloids on Visceral Blood FlowCompletedNCT01087853Phase 1, Phase 2
10Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic FibrosisActive, not recruitingNCT00677092Phase 2
11Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium LevelsCompletedNCT01014754
12Validation of a Questionnaire to Identify Signs and Symptoms of Nephrogenic Systemic FibrosisCompletedNCT00869479
13Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MRCompletedNCT01135316
14Evaluation of the Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents (GBCA)CompletedNCT00773409
15Evaluation of the Risk of NSF Following ProHance Injection in Patients With Chronic Kidney DiseaseCompletedNCT00600834
16Evaluation of the Risk of NSF Following MultiHance Injection in Patients With Chronic Kidney DiseaseCompletedNCT00600951
17Magnevist Post-marketing Surveillance in JapanCompletedNCT01376739
18Observational Post-marketing Study on the Safety and Efficacy of Dotarem® (SECURE Study)CompletedNCT01523873
19Adverse Reactions to MR and CT-examinations (Enhanced and Unenhanced)CompletedNCT01132339
20Pilot Study of the Effect of Laser on Reversing Chronic Radiation InjuryRecruitingNCT01910818
21Observational Study on the Incidence of NSF in Renal Impaired Patients Following DOTAREM AdministrationActive, not recruitingNCT01467271
22Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK InjectionSuspendedNCT00811863

Search NIH Clinical Center for Nephrogenic Systemic Fibrosis

Genetic Tests for Nephrogenic Systemic Fibrosis

About this section

Anatomical Context for Nephrogenic Systemic Fibrosis

About this section

MalaCards organs/tissues related to Nephrogenic Systemic Fibrosis:

33
Skin, Kidney, Testes, Eye, Liver, Bone, T cells

Animal Models for Nephrogenic Systemic Fibrosis or affiliated genes

About this section

MGI Mouse Phenotypes related to Nephrogenic Systemic Fibrosis:

38 (show all 16)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053709.1EPO, SMAD2, SMAD3, SMAD4, SPP1, TGFB1
2MP:00053679.0DCN, SMAD3, SMAD4, SPP1, TGFB1, TGM2
3MP:00053808.6CTGF, EPO, PIK3CA, SMAD2, SMAD3, SMAD4
4MP:00053798.4DCN, PIK3CA, SMAD2, SMAD3, SMAD4, TGFB1
5MP:00053888.2CTGF, DCN, F13A1, SMAD2, SPP1, TGFB1
6MP:00020068.0DCN, PIK3CA, SMAD2, SMAD3, SMAD4, SPP1
7MP:00053867.9DCN, PIK3CA, SMAD2, SMAD3, SMAD4, SMAD7
8MP:00107717.5CTGF, DCN, EPO, PIK3CA, SMAD2, SMAD3
9MP:00053787.2CTGF, DCN, PIK3CA, SMAD2, SMAD3, SMAD4
10MP:00053847.1CTGF, DCN, EPO, MAPKAP1, PIK3CA, SMAD2
11MP:00053897.0DCN, F13A1, PIK3CA, SMAD2, SMAD3, SMAD4
12MP:00053857.0CTGF, EPO, F13A1, PIK3CA, SMAD2, SMAD3
13MP:00053876.9CCL7, DCN, PIK3CA, SMAD2, SMAD3, SMAD4
14MP:00053766.3CTGF, DCN, EPO, F13A1, PIK3CA, SMAD2
15MP:00107686.3CTGF, DCN, EPO, F13A1, MAPKAP1, PIK3CA
16MP:00053976.3CCL7, DCN, EPO, F13A1, SMAD2, SMAD3

Publications for Nephrogenic Systemic Fibrosis

About this section

Articles related to Nephrogenic Systemic Fibrosis:

(show top 50)    (show all 403)
idTitleAuthorsYear
1
Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance(Ar)) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis? (25651409)
2015
2
Nephrogenic Systemic Fibrosis Risk After Liver Magnetic Resonance Imaging With Gadoxetate Disodium in Patients With Moderate to Severe Renal Impairment: Results of a Prospective, Open-Label, Multicenter Study. (25756684)
2015
3
Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study. (24706993)
2014
4
Substitution of gadolinium ethylenediaminetetraacetate with phosphites: towards gadolinium deposit in nephrogenic systemic fibrosis. (24132302)
2013
5
Nephrogenic systemic fibrosis in denmark- a nationwide investigation. (24349178)
2013
6
Contrast-induced nephropathy and nephrogenic systemic fibrosis: minimizing the risk. (22316507)
2012
7
Understanding nephrogenic systemic fibrosis. (23193473)
2012
8
Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. (21036418)
2011
9
Nephrogenic systemic fibrosis and gadolinium-containing radiological contrast agents: an update. (21471962)
2011
10
Quantitative assessment of dermal cellularity in nephrogenic systemic fibrosis: a diagnostic aid. (21414498)
2011
11
Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. (21724294)
2011
12
"Carcinoid-like" tricuspid valvulopathy associated with nephrogenic systemic fibrosis. (21366687)
2011
13
Gadolinium deposition in nephrogenic systemic fibrosis: an examination of tissue using synchrotron x-ray fluorescence spectroscopy. (19896750)
2010
14
Gadolinium-associated nephrogenic systemic fibrosis in patients with renal failure: the need for an interdisciplinary helping network. (20032228)
2010
15
Nephrogenic systemic fibrosis: a review. (20677539)
2010
16
Nephrogenic systemic fibrosis with a spectrum of clinical and histopathological presentation: a disorder of aberrant dermal remodeling. (19341434)
2010
17
Nephrogenic systemic fibrosis in a patient with spinal cord injury: a unique case presentation. (21145526)
2010
18
NFI_B activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. (20959327)
2010
19
MRI safety: nephrogenic systemic fibrosis and other risks. (20542435)
2010
20
Estimates of risk, empirical treatment observations, and unexpected laboratory findings reveal the complexity of nephrogenic systemic fibrosis. (19841408)
2009
21
Nephrogenic systemic fibrosis in patients with chronic kidney disease who received gadopentetate dimeglumine. (19151610)
2009
22
Effects of gadolinium contrast agents in naA^ve and nephrectomized rats: relevance to nephrogenic systemic fibrosis. (19160079)
2009
23
Nephrogenic systemic fibrosis: clinical picture and treatment. (19744598)
2009
24
High-dose gadodiamide for catheter angiography and CT in patients with varying degrees of renal insufficiency: Prevalence of subsequent nephrogenic systemic fibrosis and decline in renal function. (19457816)
2009
25
Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases. (19188312)
2009
26
Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. (19744600)
2009
27
Nephrogenic systemic fibrosis and management of high-risk patients. (19375360)
2009
28
Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron. (19789237)
2009
29
Nephrogenic systemic fibrosis: more questions and some answers. (18688172)
2008
30
Association of gadolinium based magnetic resonance imaging contrast agents and nephrogenic systemic fibrosis. (18635232)
2008
31
Nephrogenic systemic fibrosis: a new concern for rheumatologists. (18756271)
2008
32
An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital. (18328659)
2008
33
Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. (18401336)
2008
34
Nephrogenic systemic fibrosis and gadolinium: a perfect storm. (18806157)
2008
35
Epoetin and nephrogenic systemic fibrosis. (18158932)
2008
36
Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. (18690983)
2008
37
Nephrogenic systemic fibrosis: chronic imaging findings and review of the medical literature. (18324398)
2008
38
Nephrogenic systemic fibrosis associated with gadolinium use. (18400614)
2008
39
Treatment of nephrogenic systemic fibrosis with Re-PUVA. (18625379)
2008
40
Canadian Association of Radiologists national advisory on gadolinium administration and nephrogenic systemic fibrosis. (19385151)
2008
41
Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand. (18425843)
2008
42
Gadolinium-associated nephrogenic systemic fibrosis. (19920874)
2008
43
A timely reminder about an evolving clinical entity: nephrogenic systemic fibrosis and gadolinium use in CKD. (17498132)
2007
44
Treatment with corticosteroids does not seem to benefit nephrogenic systemic fibrosis. (17602192)
2007
45
Safety update on the possible causal relationship between gadolinium-containing MRI agents and nephrogenic systemic fibrosis. (17457808)
2007
46
Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. (17712863)
2007
47
Nephrogenic systemic fibrosis associated with gadolinium-containing contrast media administration in patients with reduced glomerular filtration rate. (17504326)
2007
48
The role of the hospital dermatologist in the diagnosis and treatment of calciphylaxis and nephrogenic systemic fibrosis. (18070683)
2007
49
Nephrogenic systemic fibrosis--the beginning of the end? (17572281)
2007
50
Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. (16427988)
2006

Variations for Nephrogenic Systemic Fibrosis

About this section

Expression for genes affiliated with Nephrogenic Systemic Fibrosis

About this section
Search GEO for disease gene expression data for Nephrogenic Systemic Fibrosis.

Pathways for genes affiliated with Nephrogenic Systemic Fibrosis

About this section

Pathways related to Nephrogenic Systemic Fibrosis according to GeneCards Suite gene sharing:

(show all 47)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
9.7EPO, PIK3CA, TIMP1
29.7EPO, PIK3CA, TIMP1
39.7EPO, PIK3CA, TIMP1
4
Show member pathways
9.6SMAD4, SMAD7, TGFB1
5
Show member pathways
9.6PIK3CA, SMAD3, SMAD4
69.6SMAD3, SMAD4, TGFB1
7
Show member pathways
9.6PIK3CA, SMAD2, SMAD3
8
Show member pathways
9.5SMAD2, SMAD3, SMAD4
99.5SMAD2, SMAD3, SMAD4
109.5SMAD2, SMAD3, SMAD4
119.4PIK3CA, SMAD2, SMAD4, TGFB1
129.3DCN, PIK3CA, SMAD2, TGFB1
139.3EPO, SMAD3, SMAD4, TIMP1
149.3PIK3CA, SMAD2, SMAD3, SMAD4
159.3SMAD2, SMAD3, SMAD4, TGFB1
16
Show member pathways
9.3SMAD2, SMAD3, SMAD4, TGFB1
17
Show member pathways
9.3SMAD2, SMAD3, SMAD4, TGFB1
18
Show member pathways
9.3SMAD2, SMAD3, SMAD4, TGFB1
199.3SMAD2, SMAD3, SMAD4, TGFB1
20
Show member pathways
9.3SMAD2, SMAD3, SMAD4, TGFB1
21
Show member pathways
9.3SMAD2, SMAD3, SMAD4, TGFB1
229.3SMAD2, SMAD3, SMAD4, TGFB1
239.1SMAD2, SMAD3, SMAD4, SMAD7
24
Show member pathways
9.1SMAD2, SMAD3, SMAD4, SMAD7
259.0PIK3CA, SMAD2, SMAD3, SMAD4, TGFB1
269.0PIK3CA, SMAD2, SMAD3, SMAD4, TGFB1
27
Show member pathways
9.0PIK3CA, SMAD2, SMAD3, SMAD4, TGFB1
28
Show member pathways
9.0PIK3CA, SMAD2, SMAD3, SMAD4, TGFB1
29
Show member pathways
9.0PIK3CA, SMAD2, SMAD3, SMAD4, TGFB1
30
Show member pathways
8.9SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
318.9SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
32
Show member pathways
8.9SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
338.9SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
348.9SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
358.9SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
36
Show member pathways
8.9SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
37
TGF-beta Signaling Pathway (sino)
Show member pathways
8.8SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
38
Show member pathways
8.8MAPKAP1, PIK3CA, SMAD2, SMAD3, SMAD4, TGFB1
39
Show member pathways
8.8PIK3CA, SMAD2, SMAD3, SMAD4, SPP1, TGFB1
408.7SMAD2, SMAD3, SMAD4, SMAD7, SPP1, TGFB1
41
TGF-beta signaling pathway (KEGG)
Show member pathways
8.5SMAD2, SMAD3, SMAD4, SMAD7, SPP1, TGFB1
42
Show member pathways
8.4DCN, MAPKAP1, PIK3CA, SMAD2, SMAD3, SMAD4
438.4CTGF, SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
448.4CTGF, SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
45
Show member pathways
7.3CCL7, CTGF, CXCL2, SMAD3, SMAD4, TGFB1
46
Show member pathways
7.2CCL7, CTGF, EPO, SMAD2, SMAD3, SMAD4
47
Show member pathways
6.4CCL7, CTGF, CXCL2, SMAD2, SMAD3, SMAD4

GO Terms for genes affiliated with Nephrogenic Systemic Fibrosis

About this section

Cellular components related to Nephrogenic Systemic Fibrosis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1activin responsive factor complexGO:003244410.6SMAD2, SMAD4
2SMAD2-SMAD3 protein complexGO:007114410.5SMAD2, SMAD3
3SMAD protein complexGO:007114110.2SMAD2, SMAD3, SMAD4
4platelet alpha granule lumenGO:003109310.1F13A1, TGFB1, TIMP1
5transcription factor complexGO:00056679.5SMAD2, SMAD3, SMAD4, SMAD7
6proteinaceous extracellular matrixGO:00055789.1CTGF, DCN, TGFB1, TIMP1
7extracellular spaceGO:00056157.1CCL7, CTGF, CXCL2, DCN, EPO, SPP1
8extracellular regionGO:00055766.4CCL7, CTGF, CXCL2, DCN, EPO, F13A1

Biological processes related to Nephrogenic Systemic Fibrosis according to GeneCards Suite gene sharing:

(show all 46)
idNameGO IDScoreTop Affiliating Genes
1common-partner SMAD protein phosphorylationGO:000718210.7SMAD2, TGFB1
2evasion or tolerance of host defenses by virusGO:001904910.6SMAD3, TGFB1
3positive regulation of extracellular matrix assemblyGO:190120310.6SMAD3, TGFB1
4positive regulation of SMAD protein import into nucleusGO:006039110.6SMAD4, TGFB1
5response to laminar fluid shear stressGO:003461610.6SMAD7, TGFB1
6regulation of striated muscle tissue developmentGO:001620210.6SMAD3, TGFB1
7cell activationGO:000177510.6TGFB1, TIMP1
8paraxial mesoderm morphogenesisGO:004834010.6SMAD2, SMAD3
9pathway-restricted SMAD protein phosphorylationGO:006038910.5SMAD7, TGFB1
10response to cholesterolGO:007072310.5SMAD2, TGFB1
11embryonic foregut morphogenesisGO:004861710.5SMAD2, SMAD3
12response to vitamin DGO:003328010.5SPP1, TGFB1
13primary miRNA processingGO:003105310.5SMAD2, SMAD3
14regulation of transforming growth factor beta2 productionGO:003290910.5SMAD3, SMAD4
15nodal signaling pathwayGO:003809210.4SMAD2, SMAD3
16lens fiber cell differentiationGO:007030610.4SMAD3, TGFB1
17pericardium developmentGO:006003910.4SMAD2, SMAD3
18activin receptor signaling pathwayGO:003292410.4SMAD2, SMAD3
19platelet degranulationGO:000257610.1F13A1, TGFB1, TIMP1
20developmental growthGO:004858910.0SMAD2, SMAD3, SMAD4
21response to organic substanceGO:001003310.0SPP1, TGFB1, TIMP1
22negative regulation of cell growthGO:003030810.0SMAD3, SMAD4, TGFB1
23regulation of bindingGO:005109810.0SMAD2, SMAD3, SMAD4, TGFB1
24SMAD protein complex assemblyGO:000718310.0SMAD2, SMAD3, SMAD4, TGFB1
25gastrulationGO:000736910.0SMAD2, SMAD3, SMAD4
26response to glucoseGO:00097499.9CTGF, SMAD2, TGFB1
27endoderm developmentGO:00074929.9SMAD2, SMAD3, SMAD4, TGFB1
28extracellular matrix disassemblyGO:00226179.9DCN, SPP1, TIMP1
29positive regulation of epithelial to mesenchymal transitionGO:00107189.9SMAD2, SMAD3, SMAD4, TGFB1
30SMAD protein signal transductionGO:00603959.8SMAD2, SMAD3, SMAD4, TGFB1
31negative regulation of transforming growth factor beta receptor signaling pathwayGO:00305129.8SMAD2, SMAD3, SMAD7, TGFB1
32ureteric bud developmentGO:00016579.7SMAD2, SMAD3, SMAD7, TGFB1
33response to hypoxiaGO:00016669.7EPO, SMAD3, SMAD4, TGFB1
34agingGO:00075689.7DCN, EPO, TGFB1, TIMP1
35regulation of transforming growth factor beta receptor signaling pathwayGO:00170159.6SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
36in utero embryonic developmentGO:00017019.4RCN1, SMAD2, SMAD3, SMAD4
37positive regulation of transcription, DNA-templatedGO:00458939.4EPO, SMAD2, SMAD3, SMAD4, TGFB1
38positive regulation of gene expressionGO:00106289.4CTGF, SMAD2, SMAD3, TGFB1
39platelet activationGO:00301689.4F13A1, PIK3CA, TGFB1, TIMP1
40transforming growth factor beta receptor signaling pathwayGO:00071799.3SMAD2, SMAD3, SMAD4, SMAD7, TGFB1
41extracellular matrix organizationGO:00301989.2DCN, SPP1, TGFB1, TIMP1
42transcription initiation from RNA polymerase II promoterGO:00063679.2CTGF, SMAD2, SMAD3, SMAD4, SMAD7
43wound healingGO:00420609.1DCN, F13A1, SMAD3, TGFB1, TIMP1
44inflammatory responseGO:00069548.8CCL7, CXCL2, PIK3CA, SPP1, TGFB1
45intracellular signal transductionGO:00355568.6CTGF, SMAD2, SMAD3, SMAD4, SMAD7
46negative regulation of transcription from RNA polymerase II promoterGO:00001228.4EPO, SMAD2, SMAD3, SMAD4, SMAD7, TGFB1

Molecular functions related to Nephrogenic Systemic Fibrosis according to GeneCards Suite gene sharing:

(show all 10)
idNameGO IDScoreTop Affiliating Genes
1transcription factor activity, protein bindingGO:000098810.6SMAD3, SMAD4
2transforming growth factor beta receptor, pathway-specific cytoplasmic mediator activityGO:003061810.5SMAD2, SMAD3
3enhancer bindingGO:003532610.5SMAD2, SMAD3
4protein-glutamine gamma-glutamyltransferase activityGO:000381010.4F13A1, TGM2
5co-SMAD bindingGO:007041010.4SMAD2, SMAD3
6type I transforming growth factor beta receptor bindingGO:003471310.3SMAD2, SMAD7, TGFB1
7I-SMAD bindingGO:007041110.2SMAD2, SMAD4, SMAD7
8R-SMAD bindingGO:007041210.2SMAD2, SMAD3, SMAD4
9collagen bindingGO:00055189.5DCN, SMAD3, SMAD4, SMAD7
10protein bindingGO:00055154.5CCL7, CTGF, CXCL2, DCN, EPO, MAPKAP1

Sources for Nephrogenic Systemic Fibrosis

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet